Dr. David Meyerholz is part of a multidisciplinary team that recently developed new approaches to significantly improve gene editing techniques for cells in the lung. The approach utilized membrane-penetrating shuttle peptides to enable safe delivery of gene editing ribonucleoprotein cargo into airway cells. The study was recently published in the journal Nature Communications.

Dr. Meyerholz is a Professor in the Department of Pathology and a member of the Lung Biology & Cystic Fibrosis Research Center at the University of Iowa. Collaborators on the project include a number of scientists in the Department of Pediatrics (CCOM) and at Feldon Therapeutics in Quebec, Canada.

Link to write up: https://www.sciencedaily.com/releases/2019/10/191031174655.htm

Link to paper: https://www.nature.com/articles/s41467-019-12922-y